

### REMARKS

Claims 1, 3-10, and 12-15 are pending. Claims 2, 11, and 16-19 are canceled. Upon entry of this paper, claims 1, 12, and 13 are amended.

#### Support for Amendments

Claim 1 is amended to include a preferred dose range for Et 743. Support can be found in the specification as originally filed, for example at page 7, 2<sup>nd</sup> full paragraph, page 10, Example 1, last paragraph, page 14, Example 2, middle paragraph, and page 15, Table 4. Claims 12 and 13 are amended for grammatical reasons, and to remove the word “about” with regard to various embodiments.

Applicants respectfully request entry of the amendments “after-final” as the amendments present no new issues, but rather clarify the preferred embodiments as claimed, and simplify issues for possible appeal (*i.e.*, remove the issue of the Examiner’s handling of the term “about” in the Office Action at page 6, line 9).

No new matter is added.

#### Rejection Under 35 U.S.C. § 103(a)

Claims 1, 3-10, and 12-15 are rejected under 35 U.S.C. § 103(a) as being unpatentable over WO 02/36135 (Takahashi) and WO 00/69441 (Bowman) in view of Dorr (Cancer Chemotherapy Handbook, 1994, pages 395-416).<sup>1</sup> The Office Action argues that it would have been obvious to use the dosing schedules for doxorubicin as provided by Dorr in combination with the teachings of Takahashi and Bowman for the use of Ecteinascidin 743. The Office

---

<sup>1</sup> Applicants note that the national phase entry of Takahashi is currently pending before the USPTO as US 10/416,086, and the national phase of Bowman is currently pending before the USPTO as US 09/787,461.

Action further argues that one of ordinary skill in the art would have an expectation that the toxicity of doxorubicin as a single agent would not be affected by an agent with a different mechanism of action, and therefore one would look to the dosage of doxorubicin as a single agent for guidance in determining the dosage of doxorubicin in combination with another agent.

Applicants respectfully traverse the rejection on the basis that 1) the references, either alone or in combination, fail to teach the claimed dose range for Et 743 in combination with doxorubicin; 2) the literature does not support the Office Action's findings with respect to the toxicity of doxorubicin when used in combination with agents with different mechanisms of action; and 3) Applicants have surprisingly found evidence of unexpected results within a sub-range that rebut any case of obviousness that may have been made.

The References Fail to Teach the Claimed Dose of Between 0.6 and 0.75 mg/m<sup>2</sup> for Et 743

The Office Action cites Bowman with respect to meeting the claimed dose for Et 743 in combination with doxorubicin. However, Bowman actually teaches a "recommended dose level of 1500 microgram per m<sup>2</sup> of body surface area for 24hr infusions or 1650 microgram per m<sup>2</sup> body surface area for 3 hr infusions" (see Bowman, page 12, lines 22-24). Moreover, for the 24 hour infusion, Bowman teaches a preferred range of "between 1000 and 1500 microgram per m<sup>2</sup> of body surface area," the latter being the RD (Recommended Dose) "as determined in clinical trials" (see Bowman, page 13, lines 14-18). For the 3 hr infusion, Bowman teaches a preferred range "between 1000 and 1650 microgram per m<sup>2</sup> of body surface area," the latter being the RD (Recommended Dose) "as determined in clinical trials" (see Bowman, page 13, line 19 through page 14, line 2). To be perfectly clear, both "between 1000 and 1500 micrograms per m<sup>2</sup>" and "between 1000 and 1650 microgram per m<sup>2</sup> of body surface area" are outside the claimed range

of 0.6 to 0.75 mg/m<sup>2</sup>. In other words, at no point does Bowman teach the specifically claimed dose of “between 0.6 and 0.75 mg/m<sup>2</sup>” for Et 743.

As shown above, Bowman fails to teach the claimed dose of between 0.6 and 0.75 mg/m<sup>2</sup> for Et 743, let alone the claimed dose of Et 743 in combination with about 50 mg/m<sup>2</sup> or about 60 mg/m<sup>2</sup> of doxorubicin. The deficiency of Bowman is not remedied by either Takahashi or Dorr. As a result, the Office Action can only arrive at the claimed elements through hindsight reconstruction of Applicants’ claimed invention, which is clearly improper. Therefore, Applicants respectfully request withdrawal of the rejection.

In addition to the failure of the references to teach the claimed range of Et 743, Applicants find no support for the Office Action’s argument that 60-75 mg/m<sup>2</sup> of doxorubicin from Dorr (page 399, table on lines 38-45) is equal to about 50 mg/m<sup>2</sup> as claimed (see Office Action, page 6, lines 17-20). In other words, this extension of the teachings of Dorr can only be arrived at through the Examiner’s hindsight reconstruction of Applicants’ claimed invention, which is clearly improper.

#### The Literature Does Not Support the Office Action’s Findings Regarding Doxorubicin

In the response dated April 28, 2008, Applicants argued that one would not properly combine Dorr with either Takahashi or Bowman because Dorr teaches amounts of doxorubicin as a single agent rather than in combination with other agents, and that it was known in the art that doxorubicin in combination with other anticancer agents may result in antagonism between the two agents. As evidence in support of this argument, Applicants cited Hahn et al. (see IDS of April 28, 2008), which reports less-than-additive (possibly antagonistic) cytotoxicity for the combination of paclitaxel (Taxol®) with doxorubicin against cell lines of human breast cancer,

human lung adenocarcinoma and human ovarian cancer. Each drug when given alone is known to be active against these tumor types, but from the results, Hahn concludes that certain protocols of doxorubicin and paclitaxel “would have a reduced therapeutic index because the normal tissue toxicities might be additive for the combination drug regimen,” (page 2711, left column, third full paragraph). In other words, Applicants provided evidence that the combination of doxorubicin and a second antitumor agent results in increased side effects which limit the therapeutic index of the combination.

In response, the Office Action improperly ignores the evidence provided in Hahn, and argues that Dorr teaches that the “dose limit must take into account (page 399, right column, paragraph 4) due to having the same mechanism of action (page 396, left column, paragraph 3)” (see Office Action, page 7, lines 18-20). The Office Action concludes that “one of ordinary skill in the art at the time of the invention would have a reasonable expectation that an agent that has a mechanism of action that is certainly different from doxorubicin, such as ET-743, would not affect the dose limit of doxorubicin,” (Office Action, page 8, lines 3-6). Moreover, the Office Action concludes that one of ordinary skill in the art “having an expectation that the dose limit would not be affected, would look to the dosage amount of the single agent doxorubicin as guidance for the dosage for doxorubicin in combination with an agent that has a different mechanism of action,” (Office Action, page 8, lines 6-9). For the record, Applicants note that paclitaxel, which was discussed in Applicants’ previous comments on Hahn, has a different mechanism of action than doxorubicin.<sup>2</sup> Therefore, Applicants assert that based on the evidence already of record which was improperly not considered, the Office Action’s conclusions with respect to doxorubicin dosage are contrary to the scientific literature.

---

<sup>2</sup> Paclitaxel interferes with the normal function of microtubule breakdown- see, for example, the NCI drug dictionary (<http://www.cancer.gov/drugdictionary/>).

In addition to the evidence already of record, Applicants note the following. Doxorubicin is an anthracycline antibiotic which intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis (a DNA-intercalating compound). ET-743 is the first of a new class of anti-tumor agents with a complex transcription-targeted mechanism of action. A detailed description of the mechanism of action of Et 743 can be found, for example, in Lau et al. (Clinical research 11, 672-77, 2005, provided herewith). Therefore, the literature supports the proposition that doxorubicin and ET-743 have different mechanisms of action. However, contrary to the Examiner's opinion, the finding of an effective dosage for ET-743 and doxorubicin when they are administered together is not simply based on the dosage of doxorubicin as a single agent because it is known in the art that doxorubicin in combination with other anticancer agents, having the same or a different mechanism of action, may not be beneficial or may require changes in dose.

For example, in Dorr, it is also disclosed (page 400, paragraph linking first and second columns) that drug interactions have been described when doxorubicin is administered with interferon alpha and "substantial dose reductions are required." Furthermore, in Sarosy et al. (Cancer Research 46, 5368-5371, 1986, provided herewith), a Phase I study of  $\alpha 2$ -Interferon plus doxorubicin in patients with solid tumors is described, wherein haematological toxicity was the dose limiting toxicity. Sarosy et al. concludes that "the concomitant administration of recombinant  $\alpha 2$ -Interferon severely limits the amount of doxorubicin that can be administered" (see abstracts). Moreover, in the discussion (last paragraph of the first column, page 5370) it is disclosed that although prior *in vitro* and *in vivo* data showed that doxorubicin and interferon have synergistic antitumor activity, unfortunately the concomitant administration of both drugs "severely limits the amount of doxorubicin that can be given." In addition, the maximum

tolerated doses of doxorubicin in combination with interferon and as a single agent are compared. Given concomitantly with interferon alpha every 3 weeks, the maximum tolerated dose (MTD) for doxorubicin is 40 mg/m<sup>2</sup>, which is a dosage distinctly lower than the MTD for doxorubicin as a single agent (60-90 mg/m<sup>2</sup>) for the same administration schedule. Therefore, the combination therapy using doxorubicin and interferon alpha presented unexpected side effects (*i.e.*, myelosuppression) which made it necessary to reduce doxorubicin dosage. Notably, interferon alpha binds to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element whereas doxorubicin is a DNA-intercalating antitumor agent. Accordingly, doxorubicin and interferon alpha have a different mechanism of action. Therefore, the combination of doxorubicin with an anticancer drug having a different mechanism of action (e.g., interferon alpha) may be unfavourable and require the reduction of the dosage of doxorubicin.

Similarly, undesired side effects have been observed when combining doxorubicin with vincristine, which is a natural alkaloid with antimitotic and antineoplastic activities which binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle (an antimitotic agent). Neurotoxic side effects (Boranic et al., Biomedicine, 31(5), 124-5, 1979, provided herewith) have been reported for administration of doxorubicin and vincristine as combined anticancer therapy. Boranic discloses a clinical case wherein central nervous system toxicity appeared after treating a child with acute leukaemia with doxorubicin (Adriamycin) and vincristine:

We have observed symptoms of an acute extrapyramidal lesion in a child with leukaemia treated with vincristine and adriamycin, and assume we have encountered another uncommon case of toxicity to the central nervous system. Vincristine usually causes peripheral neuropathies, while adriamycin inflicts damage to the heart

(Boranic, page 124, lines 4-10).

Thus, in view of the cited prior art, which teaches an adverse interaction between doxorubicin and other anticancer drugs, a person skilled in the art at the time of the invention would not have looked to the teachings of the single agent doxorubicin dose in Dorr for dosage information when embarking on a combination therapy using ET-743 and doxorubicin for the effective treatment of cancer in human patients. In other words, the technical literature does not support the Office Action's reliance on Dorr for determining the dosage of doxorubicin for the claimed combination. On this basis, Applicants respectfully request withdrawal of the rejection.

#### Evidence of Unexpected Results That Rebut Any Case of Obviousness

Applicants traverse the finding of obviousness. However, even if, *arguendo*, a prima facie case of obviousness had been made in the Office Action, Applicants have surprisingly found evidence of unexpected results within a sub-range that rebut any case of obviousness that may have been made. As noted by the Federal Circuit, "[t]he law is replete with cases in which the difference between the claimed invention and the prior art is some range or other variable within the claims. . . . In such a situation, the applicant must show that the particular range is critical, generally by showing that the claimed range achieves unexpected results relative to the prior art range." *In re Woodruff*, 919 F.2d 1575 (Fed. Cir. 1990). In the present case, Applicants have found that the combination of Et 743 in a dose range of 0.6 to 0.75 mg/m<sup>2</sup> for ET-743, and doxorubicin in a dose of about 50 mg/m<sup>2</sup> or about 60 mg/m<sup>2</sup> results in antitumor activity without dose-limiting toxicity. See Table 3 on page 13 of the specification as filed, which shows that five patients had confirmed partial response, and 5 patients had long-lasting stable disease after treatment as claimed. Table 4 in the specification as filed provides additional dose-limiting toxicity data. As discussed above, Applicants have provided ample evidence of combinations

with doxorubicin resulting in undesired toxicity. Therefore, Applicants have found a sub-range that rebuts any case of obviousness that may have been made, and respectfully request withdrawal of the rejection.

### **Provisional Obviousness-Type Double-Patenting**

Claims 1 and 3-9 are provisionally rejected for obviousness-type double patenting over claims 1-11 and 19-20 of US 11/577,790.

Because the rejections are provisional, Applicants respectfully request that the rejections be held in abeyance pending the determination of patentable subject matter. Applicants suggest that if all other rejections are overcome, it is appropriate to withdraw the provisional double-patenting rejections and allow the instant application to issue, as directed by the MPEP:

If a “provisional” nonstatutory obviousness-type double patenting (ODP) rejection is the only rejection remaining in the earlier filed of the two pending applications, while the later-filed application is rejectable on other grounds, the examiner should withdraw that rejection and permit the earlier-filed application to issue as a patent without a terminal disclaimer. (MPEP §804).

### **AUTHORIZATION**

The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **50-3732**, Order No. 13566.105020. In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **50-3732**, Order No. 13566.105020.



Respectfully submitted,  
King & Spalding, LLP

Dated: December 3, 2008

By: /michael willis/  
Kenneth H. Sonnenfeld / Michael A. Willis  
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:  
Customer Number 65989  
King & Spalding  
1185 Avenue of the Americas  
New York, NY 10036-4003  
(212) 556-2100 Telephone  
(212) 556-2222 Facsimile